What are the contraindications to combined oral contraceptives?

Contraindications to Combined Oral Contraceptives

Combined oral contraceptives are absolutely contraindicated (Category 4) in women with conditions that pose unacceptable health risks, including cardiovascular disease with thrombotic risk, severe liver disease, current breast cancer, and migraine with aura, while relative contraindications (Category 3) include conditions where risks usually outweigh benefits such as controlled hypertension and certain postpartum states. 1

Understanding the Classification System

The U.S. Medical Eligibility Criteria uses a 4-category system to classify contraindications 2:

• Category 1: No restrictions for use
• Category 2: Advantages generally outweigh theoretical or proven risks
• Category 3: Theoretical or proven risks usually outweigh advantages (relative contraindications)
• Category 4: Unacceptable health risk if method is used (absolute contraindications)

Absolute Contraindications (Category 4)

Cardiovascular and Thrombotic Conditions

Age and smoking: Women ≥35 years smoking ≥15 cigarettes daily face unacceptable cardiovascular risk, primarily myocardial infarction and stroke 2, 1

Thrombotic disease:

• Acute VTE or history of VTE with ≥1 risk factor for recurrence (including estrogen-related VTE, pregnancy-related VTE, known thrombophilia, active cancer, or recurrent VTE) 1
• Known thrombogenic mutations (factor V Leiden, prothrombin mutation, protein S/C deficiency, antithrombin deficiency) 1
• Major surgery with prolonged immobilization 1

Cardiovascular disease:

• Current or history of ischemic heart disease 1
• Current or history of stroke 1
• Valvular heart disease with complications (pulmonary hypertension, atrial fibrillation risk, or history of subacute bacterial endocarditis) 1
• Multiple risk factors for atherosclerosis (older age, smoking, diabetes, hypertension, dyslipidemia) 1

Hypertension: Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg, or vascular disease 1

Hepatic Conditions

• Acute or flare of viral hepatitis 1
• Severe or decompensated cirrhosis 1
• Hepatocellular adenoma 1
• Malignant liver tumor (hepatoma) 1

Metabolic and Endocrine

Diabetes mellitus with nephropathy, retinopathy, neuropathy, other vascular disease, or duration ≥20 years 1

Oncologic

• Current breast cancer 1

Neurologic

Migraine with aura at any age represents an absolute contraindication due to increased stroke risk 1. This is particularly important as women with migraine using estrogen-containing contraceptives face significantly elevated ischemic stroke risk 3.

Postpartum Period

≤21 days postpartum, regardless of breastfeeding status, due to elevated VTE risk 1

Autoimmune and Transplant

• Systemic lupus erythematosus with positive or unknown antiphospholipid antibodies 1, 4
• Solid organ transplantation complicated by acute or chronic graft failure, rejection, or cardiac allograft vasculopathy 1
• Multiple sclerosis with prolonged immobility 1

Cardiac

Peripartum cardiomyopathy with normal or impaired cardiac function for ≤6 months, or moderate to severely impaired cardiac function at any time 1

Relative Contraindications (Category 3)

Cardiovascular

• Age ≥35 years smoking <15 cigarettes daily 1
• Systolic BP 140-159 mmHg or diastolic BP 90-99 mmHg 1
• Adequately controlled hypertension 1
• VTE with no risk factors for recurrence 1
• Superficial venous thrombosis 1

Postpartum States

• Breastfeeding 21-29 days postpartum 1
• Breastfeeding 30-42 days postpartum with other VTE risk factors (age ≥35, previous VTE, thrombophilia, immobility, BMI ≥30 kg/m², postpartum hemorrhage, post-Cesarean, preeclampsia, smoking) 1
• Non-breastfeeding 21-42 days postpartum with other VTE risk factors 1

Oncologic

Past breast cancer with no evidence of disease for 5 years 1

Critical Clinical Considerations

Pre-Prescription Assessment

Before prescribing COCs, obtain 1:

• Comprehensive medical history focusing on cardiovascular, thrombotic, hepatic, and neurologic conditions
• Blood pressure measurement (essential—unrecognized hypertension is the most common missed contraindication) 1, 5, 6
• Pregnancy status assessment (clinical criteria or urine test)

Important: Pelvic examination, breast examination, cervical cancer screening, and STI screening are NOT required before COC initiation 1.

Common Pitfalls

Research shows that approximately 31% of women using COCs have at least one contraindication 7. The most commonly missed contraindications include:

1. Unrecognized hypertension (most prevalent—affects 5.6-9.8% of users) 5, 6
2. Migraine misclassification (women often cannot distinguish migraine with aura from other headaches) 6
3. Age-related smoking risk (women ≥35 years who smoke) 7, 5

High-Risk Populations

Women at increased risk for contraindications include 7, 5:

• Married women (OR 2.19)
• Age ≥35 years (OR 2.33-5.30)
• Women with ≥1 live birth (OR 2.19)
• BMI ≥30 (OR 2.24)

Drug Interactions Affecting Safety

Category 3 interactions (risks usually outweigh benefits) 8:

• Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine)
• Rifampin or rifabutin therapy
• Lamotrigine (COCs reduce lamotrigine levels, increasing seizure risk)

Special Populations

Systemic lupus erythematosus: Strongly recommend against COCs in patients with positive antiphospholipid antibodies due to thrombosis risk. Use progestin-only methods or IUDs instead 4.

Acne treatment context: When prescribing COCs exclusively for acne (not contraception), the risk-benefit calculation differs—compare COC risks against acne consequences, not pregnancy risks 1. Consider whether alternative acne treatments might be safer.

Cardiovascular Risk Context

While COCs increase VTE risk approximately 2-6 fold over baseline, the absolute risk remains low in healthy reproductive-aged women (baseline annual risk 1/10,000) 4, 9. However, combined oral contraceptives containing third-generation progestogens (desogestrel, gestodene) carry higher VTE risk than second-generation formulations (levonorgestrel, norgestrel) 9.